Literature DB >> 8995607

RNA-targeted activators, but not DNA-targeted activators, repress the synthesis of short transcripts at the human immunodeficiency virus type 1 long terminal repeat.

P S Pendergrast1, N Hernandez.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) promoter directs the synthesis of two types of RNA molecules: full-length transcripts, whose synthesis is activated by the viral activator Tat, and short transcripts, whose synthesis is dependent on the inducer of short transcripts (IST), a bipartite DNA element located in large part downstream of the HIV-1 transcriptional start site. In the absence of Tat, short transcripts constitute the large majority of the RNA molecules synthesized from the HIV-1 promoter. In the presence of Tat, synthesis of the short transcripts is repressed and synthesis of the full-length transcripts is activated. Tat is unique among transcriptional activators in acting through an RNA target, the TAR element. However, Tat has been shown to activate transcription from a DNA target when fused to the appropriate DNA binding domain, raising the question of why Tat has been directed to the RNA. Here we have compared the abilities of Tat and other RNA- and DNA-bound activators to stimulate transcription from the HIV-1 promoter. We show that DNA-targeted activators, including DNA-targeted Tat, activate the synthesis of both short and long transcripts, while RNA-targeted Tat and another RNA-targeted activator activate the synthesis of full-length transcripts but specifically repress that of short transcripts. The unique ability of RNA-targeted activators to down-regulate short transcript synthesis suggests that Tat is directed to the RNA specifically for the purpose of repressing short transcripts.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8995607      PMCID: PMC191138     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  RNA transcripts of the human immunodeficiency virus transactivation response element can inhibit action of the viral transactivator.

Authors:  G J Graham; J J Maio
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

2.  Synergistic activation of the human immunodeficiency virus type 1 promoter by the viral Tat protein and cellular transcription factor Sp1.

Authors:  J Kamine; G Chinnadurai
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

Review 3.  Control of RNA initiation and elongation at the HIV-1 promoter.

Authors:  K A Jones; B M Peterlin
Journal:  Annu Rev Biochem       Date:  1994       Impact factor: 23.643

4.  Direct evidence for translational regulation by leader RNA and Tat protein of human immunodeficiency virus type 1.

Authors:  D N SenGupta; B Berkhout; A Gatignol; A M Zhou; R H Silverman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

5.  Synergy between HIV-1 Tat and adenovirus E1A is principally due to stabilization of transcriptional elongation.

Authors:  M F Laspia; A P Rice; M B Mathews
Journal:  Genes Dev       Date:  1990-12       Impact factor: 11.361

6.  Single cell transcript analysis of human immunodeficiency virus gene expression in the transition from latent to productive infection.

Authors:  H Peng; T A Reinhart; E F Retzel; K A Staskus; M Zupancic; A T Haase
Journal:  Virology       Date:  1995-01-10       Impact factor: 3.616

7.  The yeast UASG is a transcriptional enhancer in human HeLa cells in the presence of the GAL4 trans-activator.

Authors:  N Webster; J R Jin; S Green; M Hollis; P Chambon
Journal:  Cell       Date:  1988-01-29       Impact factor: 41.582

8.  Formation of a small ribonucleoprotein particle between Tat protein and trans-acting response element in human immunodeficiency virus-infected cells.

Authors:  K Pfeifer; M Bachmann; H C Schröder; B E Weiler; D Ugarkovic; T Okamoto; W E Müller
Journal:  J Biol Chem       Date:  1991-08-05       Impact factor: 5.157

9.  Formation of the 3' end of U1 snRNA is directed by a conserved sequence located downstream of the coding region.

Authors:  N Hernandez
Journal:  EMBO J       Date:  1985-07       Impact factor: 11.598

10.  HIV-1 Tat protein promotes formation of more-processive elongation complexes.

Authors:  R A Marciniak; P A Sharp
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more
  8 in total

Review 1.  P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II.

Authors:  D H Price
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

2.  FBI-1 can stimulate HIV-1 Tat activity and is targeted to a novel subnuclear domain that includes the Tat-P-TEFb-containing nuclear speckles.

Authors:  P Shannon Pendergrast; Chen Wang; Nouria Hernandez; Sui Huang
Journal:  Mol Biol Cell       Date:  2002-03       Impact factor: 4.138

3.  Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro.

Authors:  Y Zhu; T Pe'ery; J Peng; Y Ramanathan; N Marshall; T Marshall; B Amendt; M B Mathews; D H Price
Journal:  Genes Dev       Date:  1997-10-15       Impact factor: 11.361

4.  Utilization of a mammalian cell-based RNA binding assay to characterize the RNA binding properties of picornavirus 3C proteinases.

Authors:  W S Blair; T B Parsley; H P Bogerd; J S Towner; B L Semler; B R Cullen
Journal:  RNA       Date:  1998-02       Impact factor: 4.942

5.  Purification and characterization of FBI-1, a cellular factor that binds to the human immunodeficiency virus type 1 inducer of short transcripts.

Authors:  F Pessler; P S Pendergrast; N Hernandez
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

6.  Promoter activity of Tat at steps subsequent to TATA-binding protein recruitment.

Authors:  H Xiao; J T Lis; K T Jeang
Journal:  Mol Cell Biol       Date:  1997-12       Impact factor: 4.272

7.  Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo.

Authors:  Kara G Lassen; Justin R Bailey; Robert F Siliciano
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

Review 8.  The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention.

Authors:  Miguel Stevens; Erik De Clercq; Jan Balzarini
Journal:  Med Res Rev       Date:  2006-09       Impact factor: 12.944

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.